DOI: 10.36347/sjams.2019.v07i05.017

Pages: 1770-1774

A clinical trial was carried out in the Department of Dermatology and Venereology, Cumilla Medical College Hospital; Cumilla, Bangladesh during the period from July 2018 to December 2018. Total sixty (60) patients of clinically diagnosed mild to moderate acne vulgaris was enrolled and thirty (30) of Group I patients were treated by dapsone gel, 7.5% and another thirty of Group II patients were treated by Clyndamycin cream over 28 days in patients with moderate acne vulgaris. Our objectives were to assess the efficacy and safety of dapsone gel, 7.5% on the Treatment of Acne Vulgaris. At baseline mean number of comedones in Group I and Group II was 13.11±3.67 and 12.12±3.61, respectively (p=0.415) and at final follow-up 4.10±4.11 and 4.50±3.10 in each group (p>0.05). At baseline mean number of papules in Group I and Group II was 18.11±9.48 and 19.01±13.44, respectively (p=0.725) and at final follow-up 8.02±7.69 and 8.03±9.68 (p>0.05). At baseline mean number of pustules in Group I and Group II was 0.49±1.43 and 0.50±1.31, respectively (p=0.897) and at final follow-up 0.08±0.36 and 0.00 (p>0.05). At baseline mean of total acne score was 29.96±14.23 and 30.90±17.17 in Group I and Group II and at final follow-up it was 11.87±12.04 and 11.20±13.85, respectively in Group I and Group II (p>0.05). Percent reduction of acne severity from baseline to final follow-up was 69.20±23.41 in Group I and 74.77±23.30 in Group II (p=0.393). At final follow-up 56.7% of Group I and 63.3% of Group II achieved excellent response and 13.3% of Group I and 16.7% of Group II achieved good response. It can be concluded dapsone gel 7.5% was found to be more effective than Clyndamycin cream in the treatment of acne vulgaris.